Pfizer’s monthly obesity injection drove shows promise in trial
Smith Collection | Archive Photos | Getty Images Pfizer on Thursday said its experimental obesity drug, which it…
Eli Lilly CEO David Ricks talks Medicare coverage of obesity pills
Eli Lilly CEO Dave Ricks on Friday said upcoming Medicare coverage of obesity drugs could be a major…
Eli Lilly plans $3.5 billion Pennsylvania plant for obesity drugs
Eli Lilly Chair and CEO Dave Ricks speaks during a press conference in Houston, Sept. 23, 2025. Antranik…
I talked to many health CEOs out West and see big things for drug stocks
We get so caught up in the buzz and the sizzle that we forget about the steak, especially…
Novo Nordisk shares rise after Wegovy obesity pill launch
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, US, on Thursday, Jan.…
First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the…
Novo Nordisk beyond weight loss has investors wary, scientists hopeful
Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood…
Global stocks powered through 2025, but the real test may come in 2026
Global stocks have seen a stellar run in 2025, yet widening performance gaps and rising expectations suggest the…
Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill…
Obesity pills from Novo Nordisk, Eli Lilly are coming
Daniel Grill | Tetra Images | Getty Images A version of this article first appeared in CNBC’s Healthy…
WHO backs use of GLP-1 therapies for obesity, warns access will remain limited
A view shows The World Health Organization (WHO) headquarters in Geneva, Switzerland, Jan. 28, 2025. Denis Balibouse |…
5 things to know before the stock market opens Monday
Sopa Images | Lightrocket | Getty Images This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in…